Cetuximab and panitumumab are monoclonal antibodies targeting the epidermal growth factor receptor (EGFR) and have demonstrated survival benefits in randomized control trials (RCT) of metastatic colorectal cancer (mCRC). Since 2008, retrospective analyses of previous RCT have shown that cetuximab and panitumumab are contraindicated in patients with *KRAS* exon 2 (codons 12 and 13) mutations. Moreover, patients with *KRAS* mutations exhibited detrimental effects on receiving oxaliplatin, folic acid, and infusional 5-FU (FOLFOX4) plus cetuximab or panitumumab compared with FOLFOX4 alone. Since the Japanese Society of Medical Oncology (JSMO) published "Japanese guidelines for testing of *KRAS* gene mutation in colorectal cancer" in 2008, testing for *KRAS* mutation prior to anti-EGFR antibody therapy has been widely accepted in clinical practice and three types of quality-assured diagnostic kits have been approved in Japan (Table[1](#tbl1){ref-type="table"}).

###### 

Summary of the commonly used assays in Japan for KRAS testing of colorectal cancer

  Assay                           Sanger sequencing        PCR-rSSO           Scorpion-ARMS                                                F-PHFA
  ------------------------------- ------------------------ ------------------ ------------------------------------------------------------ ------------------
  Commercial diagnostic kit       ―                        MEBGEN KRAS        TheraScreen: K-RAS Mutation Kit DxS-QIAGEN, Manchester, UK   OncoGuide KRAS
  Limit of detection (%)          10--25                   5                  1--5                                                         5--10
  Detectable types of mutations   All types of mutations   G12S, G12C, G12R   G12S, G12C, G12R                                             G12S, G12C, G12R
                                                           G12D, G12V, G12A   G12D, G12V, G12A                                             G12D, G12V, G12A
                                                           G13S, G13C, G13R   G13D                                                         G13D
                                                           G13D, G13V, G13A                                                                

A therapeutic strategy for mCRC has been continuously improved since the publication of the Japanese guidelines. In addition, patients with *KRAS* or *NRAS* mutations except those with *KRAS* exon 2 mutations are reported to be primarily resistant to anti-EGFR antibody therapies.[@b2],[@b3] Because these patients account for approximately 20% of *KRAS* exon 2 wild-type patients, "minor" *RAS* mutations are not negligible in daily clinical practice.

The Japanese Society of Medical Oncology established a working group to revise *KRAS* guidelines in December 2013, and published a revised version of the guidelines in April 2014 after independent review and public comments. Here, we summarize the new clinical guidelines. Additional references related to each section are listed as supplemental information.

Basic Requirements for Testing *RAS* Mutations
==============================================

Anti-epidermal growth factor receptor antibody therapy may be ineffective in terms of survival benefit and/or tumor shrinkage in patients with expanded *RAS (KRAS/NRAS)* mutations. Randomized control trials (RCT) of chemotherapy with or without anti-EGFR antibody in mCRC revealed that anti-EGFR antibody had no benefit on the response rate, progression-free survival and overall survival in patients with *KRAS* exon 2 (codons 12 and 13) mutations.[@b4] This finding is consistent with other anti-EGFR therapies, including cetuximab or panitumumab, therapeutic lines and combined chemotherapies. Although increased survival with cetuximab of the patients with *KRAS* codon 13 (G13D) mutation was reported,[@b5] patients with any *KRAS* exon 2 mutations are unlikely to benefit from cetuximab or panitumumab.[@b6] Therefore, anti-EGFR antibody therapy is not recommended for patients with *KRAS* exon 2 mutations.

Since 2013, prospective-retrospective analyses of phase III studies have revealed that patients with wild-type *RAS* were expected to benefit from panitumumab, although benefits were not obtained in patients with mutations including *KRAS* exons 3 and 4, and *NRAS* exons 2, 3 and 4, similar to patients with *KRAS* exon 2 mutations (Tables[2](#tbl2){ref-type="table"} and [3](#tbl3){ref-type="table"}).[@b2]

###### 

Therapeutic effects on wild type *RAS*

                    RAS ascertainment[†](#tf2-1){ref-type="table-fn"}   Regimen          *n*          RR (%)   PFS (M)   HR                         OS (M)   HR
  ----------------- --------------------------------------------------- ---------------- ------------ -------- --------- -------------------------- -------- --------------------------
  PRIME             90% (1060/1183)                                     FOLFOX4          253          ---      7.9       HR 0.72 (*P *=* *0.004)    20.2     HR 0.78 (*P *=* *0.04)
  FOLFOX4 + Pmab    259                                                 ---              10.1         26.0                                                   
  20050181          85% (1008/1186)                                     FOLFIRI          211          10       4.4       HR 0.695 (*P *=* *0.006)   13.9     HR 0.803 (*P *=* *0.08)
  FOLFIRI + Pmab    204                                                 41               6.4          16.2                                                   
  20020408          82% (378/463)                                       BSC              63           0        7 weeks   HR 0.36 (*P *\< 0.0001)    ---      ---
  BSC + Pmab        73                                                  16               14.1 weeks   ---                                                    
  OPUS              75% (254/337)                                       FOLFOX4          49           28.6     5.8       HR 0.53 (*P *=* *0.0615)   17.8     HR 0.94 (*P *=* *0.80)
  FOLFOX4 + Cmab    38                                                  57.9             12.0         19.8                                                   
  CRYSTAL           69% (827/1198)                                      FOLFIRI          189          38.6     8.4       HR 0.56 (*P *=* *0.0002)   20.2     HR 0.69 (*P *=* *0.0024)
  FOLFIRI + Cmab    178                                                 66.3             11.4         28.4                                                   
  PEAK              82% (233/285)                                       mFOLFOX6 + Bev   82           54       10.1      HR 0.66 (*P *=* *0.03)     28.9     HR 0.63 (*P *=* *0.06)
  mFOLFOX6 + Pmab   88                                                  58               13.0         41.3                                                   
  FIRE-3            69% (520/752)                                       FOLFIRI + Bev    171          59.6     10.2      HR 0.93 (*P *=* *0.54)     25.6     HR 0.70 (*P *=* *0.011)
  FOLFIRI + Cmab    171                                                 65.5             10.4         33.1                                                   

*RAS* ascertainment: ratio of randomized patients whom *RAS* mutations were evaluated. Bev, bevacizumab; Cmab, cetuximab; HR, hazard ratio; OS, overall survival; PFS, progression free survival; Pmab, panitumumab; RR, response rate.

###### 

Therapeutic effects on mutant *RAS*

                   Regimen       *n*    RR (%)      PFS (M)     HR                         OS (M)   HR
  ---------------- ------------- ------ ----------- ----------- -------------------------- -------- --------------------------
  PRIME            FOLFOX4       276    ---         8.7         HR 1.31 (*P *=* *0.008)    19.2     HR 1.25 (*P *=* *0.034)
  FOLFOX4 + Pmab   272           ---    7.3         15.6                                            
  20050181         FOLFIRI       294    13          4.0         HR 0.861 (*P *=* *0.14)    11.1     HR 0.914 (*P *=* *0.34)
  FOLFIRI + Pmab   299           15     4.8         11.8                                            
  20020408         BSC           114    0           7.3 weeks   HR 0.97 (*P *=* *0.729)    ---      ---
  BSC+Pmab         99            1      7.4 weeks   ---                                             
  OPUS             FOLFOX4       75     50.7        7.8         HR 1.54 (*P *=* *0.0309)   17.8     HR 1.29 (*P *=* *0.1573)
  FOLFOX4+Cmab     92            37.0   5.6         13.5                                            
  CRYSTAL          FOLFIRI       214    36.0        7.5         HR 1.10 (*P *=* *0.47)     17.7     HR 1.05 (*P *=* *0.64)
  FOLFIRI+Cmab     246           31.7   7.4         16.4                                            
  FIRE-3           FOLFIRI+Bev   86     51.2        10.1        HR 1.31 (*P *=* *0.085)    20.6     HR 1.09 (*P *=* *0.60)
  FOLFIRI+Cmab     171           65.5   10.4        33.1                                            

Bev, bevacizumab; Cmab, cetuximab; HR, hazard ratio; OS, overall survival; PFS, progression free survival; Pmab, panitumumab; RR, response rate.

Retrospective analyses of RCT suggested that cetuximab also has a favorable survival impact only in patients with wild-type *RAS*. Furthermore, two RCT that compared anti-EGFR antibody therapy to bevacizumab revealed that a subgroup of patients with *RAS* mutations, except those with *KRAS* exon 2 mutations, did not show benefits.[@b3] Based on these results, anti-EGFR antibody therapy is ineffective in patients with previously known *KRAS* exon 2 mutations or those with mutations in *KRAS* exons 3 and 4 and *NRAS* exons 2, 3 and 4. *In vitro* studies revealed that the overexpression of *KRAS* transgenes with mutations in codons 12, 13, 59, 61, 117 and 146 induced constitutive RAS protein activation; however, the impact of individual mutations on the therapeutic efficacy remains unclear. While several patients with *KRAS* codon 146 mutation respond to anti-EGFR antibody therapy,[@b7] we assume that further subgroup analyses of RCT may provide information to conclude these issues. Thus, current procedures to detect only *KRAS* exon 2 mutations are insufficient for selecting appropriate patients. Additional testing of expanded *KRAS/NRAS* mutations is recommended.

Clinicians should properly interpret the immeasurable or unmeasured mutation status. When one or some exons/codons have undetermined mutational statuses while all the other evaluable exons are determined as *RAS* wild-type, these patients should be diagnosed as *RAS* unknown ([Table S1](#sd2){ref-type="supplementary-material"}). Potential causes of the failures are sample and/or technical issues of testing. If the test failure is due to the sample, re-examination using the remnant or newly obtained tumor samples should be considered. If the test failure is due to technical problems, re-examination should be performed with other methods. Indications for anti-EGFR antibody therapy for patients with *RAS* unknown status should be determined according to: (i) the reported frequency of mutations of immeasurable or unmeasured codons; (ii) evidence of no expected effects on patients if they have *RAS* mutations in immeasurable or unmeasured codons; (iii) side effects of anti-EGFR antibody therapy; and (iv) alternative therapeutic options except anti-EGFR antibody therapy.

Repeated tests are not required for the detection; tissue materials of either primary or metastatic lesions are applicable for *RAS* mutation testing. Evaluating *RAS* mutations prior to anti-epidermal growth factor receptor antibody therapy is recommended. *RAS* mutation is an early event in the tumorigenesis, and the frequency of *RAS* mutations might not be altered in any clinical stage ([Table S2](#sd3){ref-type="supplementary-material"}). The frequency of *KRAS* exon 2 mutations is approximately 35--40% in colorectal cancer patients, and the frequency of other *RAS* mutations is 10--15%; the same trend exists in Europe and the USA, and Japan (Table[4](#tbl4){ref-type="table"}).[@b8]

###### 

Frequencies of exon mutations

             *KRAS* exon 2 (%)   *KRAS* exon 3 (%)   *KRAS* exon 4 (%)   *NRAS* exon 2 (%)   *NRAS* exon 3 (%)   *NRAS* exon 4 (%)   Total[†](#tf4-1){ref-type="table-fn"}   Method
  ---------- ------------------- ------------------- ------------------- ------------------- ------------------- ------------------- --------------------------------------- -------------------------------------------------
  PRIME      40 (440/1096)       4 (24/638)          6 (36/620)          3 (22/637)          4 (26/636)          0 (0/629)           17                                      Sanger SURVEYOR
  20050181   45 (486/1083)       4.4 (24/548)        7.7 (41/534)        2.2 (12/536)        5.6 (30/540)        0 (0/532)           20                                      Sanger SURVEYOR
  20020408   43 (184/427)        4.8 (8/166)         5.0 (9/180)         4.2 (7/166)         3.0 (5/168)         1.1 (2/180)         18                                      Sanger[‡](#tf4-2){ref-type="table-fn"} SURVEYOR
  OPUS       43 (136/315)        6.8                 9.3                 6.8                 5.1                 0.8                 26                                      BEAMing
  CRYSTAL    37 (136/315)        3.3                 5.6                 3.5                 2.8                 0.9                 15                                      BEAMing
  PEAK       N/A                 4 (9/225)           7 (17/223)          5 (12/224)          6 (13/225)          0 (0/223)           22                                      Sanger SURVEYOR
  FIRE-3     N/A                 4.3 (21/431)        4.9 (24/458)        3.8 (18/464)        2 (10/468)          0 (0/458)           16                                      Pyrosequencing

*KRAS/NRAS* mutation ratio in wild type *KRAS* exon 2.

Next generation sequencers were used to confirm some of codon mutations.

The concordance rate of the mutation status between primary tumors and metastatic sites reached 93% by meta-analysis.[@b9] *RAS* mutational status of tumor tissue from endoscopic biopsies and matched resected specimens is highly concordant and the concordant rate is ≥97%. The mutational status of *RAS* was not altered by chemotherapy without cetuximab or panitumumab, whereas chemotherapies including cetuximab or panitumumab reportedly induced secondary *RAS* mutation and amplification. The clinical implications of the secondary *RAS* mutation, including the potential efficacy of anti-EGFR antibody therapy, remain unknown. Based on these findings, repeated testing of *RAS* mutations is currently not recommended.

Direct sequencing with manual dissection or allele-specific PCR-based methods is currently applicable for *RAS* mutation testing. Direct sequencing is able to detect both known and unknown gene mutations, whereas the detection sensitivity of the assay is limited to 10--25%, which is less sensitive than that of allele-specific PCR-based methods. Therefore, direct sequencing requires the condensation of tumor cells by manual dissection of the tissue sections in which tumor cells are densely contained (manual microdissection).[@b10] A multiplex mutation detecting kit using Luminex technology (Mebgen Rasket Kit; Medical and Biological Laboratories, Nagoya, Japan) has been approved for the simultaneous detection of 48 types of *RAS* mutations.[@b8]

In previous clinical studies, *RAS* testing was performed using various assays (Table[4](#tbl4){ref-type="table"}). The detection limit of these methods was within 10--25% (direct sequencing) to \<1% (BEAMing method) and that of the other methods was within 1--10%. Regardless of the difference in the detection limit between each method, the subgroup analyses of these RCT consistently demonstrated that *RAS* status is a predictive factor for anti-EGFR antibody therapy. Therefore, while the most suitable detection sensitivity remains to be determined, the detection limit within 1--10% should be practically considered for *RAS* mutation testing.

Thinly sliced sections of formalin-fixed, paraffin-embedded tissue blocks are applicable for *RAS* mutation testing. One section should be stained with H&E and provided for histological examination to confirm whether tissue contains a sufficient amount of tumor cells for testing. The paraffin-embedded (FFPE) tissue sample is widely used as a sample for *RAS* mutation testing. If sufficient tumor cells are confirmed histologically, the use of fresh frozen tissue samples will also be considered.

It is recommended to select tissue sections containing ≥50% tumor cells estimated by the area of tumor cells. When performing *RAS* mutation testing using sections with fewer tumor cells coupled with low sensitivity methods, manual microdissection should be performed to increase tumor cell/non-tumor cell ratio. Samples with apoptosis and necrosis are unsuitable due to the degradation of genomic DNA. If multiple samples are obtained from the same patient, select the sample that was archived for a shorter period, has a higher tumor cell ratio, and has fewer effects of prior chemotherapy or radiotherapy. These parameters should be discussed with the pathologists and laboratory staff prior to *RAS* mutation testing.

Formalin fixation leads to DNA fragmentation in FFPE tissue block samples. Thus, sample fixation (e.g. formaldehyde concentration, buffered or non-buffered formalin, duration of fixation, tissue size and sample segmentation) should be carefully considered. Using a 10% buffered formaldehyde solution is recommended. The duration of fixation is dependent on the sample size. In general, 6--48 h of fixation is recommended.

*RAS* mutation testing must be performed in laboratories well-qualified to perform both the testing procedures and specimen management. The clinical laboratories should verify the quality of testing procedures. Clinical laboratories are recommended to obtain a certificate of International Standard (e.g. ISO/IEC 17025, ISO 15189) from the International Organization for Standardization (ISO). The laboratories should undergo regular evaluations by authorized inspectors to maintain laboratory quality. Quality assurance (QA) should adhere to both international OECD and Japanese guidelines.

Testing must be performed according to standard operation procedures. The items suggested in the European QA program ([Table S3](#sd4){ref-type="supplementary-material"}) are used for the validation of testing procedures. Finally, the items shown in [Table S4](#sd5){ref-type="supplementary-material"} should be included in the report of *RAS* mutation testing.
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